Cybin, Inc. (TSE:CYBN) has released an update.
Cybin Inc., a biopharmaceutical company focusing on psychedelic-based treatments, has announced a forthcoming conference call and webcast to discuss the latest results from its Phase 2 trial of CYB003 for Major Depressive Disorder. The event will cover the four-month durability findings and will feature key company executives, including CEO Doug Drysdale and CMO Amir Inamdar. Investors and interested parties are invited to tune in to the update on March 13, 2024.
For further insights into TSE:CYBN stock, check out TipRanks’ Stock Analysis page.
